Expertise
AsteriaPharma combines expertise in the field of, nucleotide biochemistry, applied immunology, molecular and cell biology, genomics, virology, and drug design technologies.
To date, we have developed and patented modified derivatives of gemcitabine with enhanced antiproliferative activity and reduced nuclease susceptibility compared with gemcitabine (gemcitabine derivatives AP-111 and AP-112 / small molecule platform based on oligonucleotides) (European Patent EP No. 2 854 864 B1)
We have started two SARS-CoV-2 research projects aimed at
• Identifying epitopes targeted by cytotoxic T cells
• Neutralize and induce immune responses to the virus